siRNA delivery systems for cancer treatment

Advanced Drug Delivery Reviews

Volumn 61, Issue 10, 2009, Pages 850-862

  Oh, Yu Kyoung ^a   Park, Tae Gwan ^b  

^a Korea University   (South Korea)

^b Korea Advanced Institute of Science and Technology (KAIST)   (South Korea)

Author keywords

Cancer; Lipoplex; Polyplex; RNA interference; siRNA delivery; Targeted delivery

Indexed keywords

CANCER; LIPOPLEX; POLYPLEX; RNA INTERFERENCE; SIRNA DELIVERY; TARGETED DELIVERY;

CHEMICAL MODIFICATION; DRUG DELIVERY; NANOSYSTEMS; NUCLEIC ACIDS; OLIGONUCLEOTIDES; RNA;

DISEASES;

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; AGENTS ACTING ON THE EYE; AGN 211745; AKLI 5; ALN RSV 01; ANTINEOPLASTIC AGENT; APOLIPOPROTEIN A1; AZIRIDINE; BEVACIZUMAB; BEVASIRANIB; CALAA 01; CHITOSAN; CHOLESTEROL ESTER; CYCLODEXTRIN; DERMATOLOGICAL AGENT; ERLOTINIB; GEFITINIB; LIPID; LIPOSOME; MACROGOL; NANOPARTICLE; POLYETHYLENEIMINE; POLYMER; RTP 801I 14; SIRNA 027; SMALL INTERFERING RNA; TD 101; UNCLASSIFIED DRUG; UNINDEXED DRUG; URINARY TRACT AGENT; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ACUTE KIDNEY FAILURE; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GENE THERAPY; CANCER INHIBITION; CHEMICAL MODIFICATION; CLINICAL TRIAL; CONGENITAL PACHYONYCHIA; DIABETIC MACULAR EDEMA; DRUG BINDING SITE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; FEMALE GENITAL TRACT TUMOR; HUMAN; IN VIVO STUDY; LIVER CANCER; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR MECHANICS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY TRACT DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; REVIEW; RNA INTERFERENCE; SOLID TUMOR; UTERINE CERVIX CANCER; VIRUS INFECTION;

ANIMALS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HUMANS; NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 67649295505     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2009.04.018     Document Type: Review

References (131)

1. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., and Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391 (1998) 806-811
2. Doi N., Zenno S., Ueda R., Ohki-Hamazaki H., Ui-Tei K., and Saigo K. Short-interfering RNA-mediated gene silencing in mammalian cells requires Dicer and eIF2C translation initiation factors. Curr. Biol. 12 (2003) 41-46
3. Hammond S.M., Bernstein E., Beach D., and Hannon G.J. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 404 (2000) 293-296
4. Liu J., Carmell M.A., Rivas F.V., Marsden C.G., Thomson J.M., Song J.J., Hammond S.M., Joshua-Tor L., and Hannon G.J. Argonaute2 is the catalytic engine of mammalian RNAi. Science 305 (2004) 1437-1441
5. Meister G., Landthaler M., Patkaniowska A., Dorsett Y., Teng G., and Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol. Cell. 15 (2004) 185-197
6. Parker J.S., Roe S.M., and Barford D. Crystal structure of a PIWI protein suggests mechanisms for siRNA recognition and slicer activity. EMBO J. 23 (2004) 4727-4737
7. Ma J.B., Yuan Y.R., Meister G., Pei Y., Tuschl T., and Patel D.J. Structural basis for 5'-end-specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature 434 (2005) 666-670
8. Zamore P.D., and Haley B. Ribo-gnome: the big world of small RNAs. Science 309 (2005) 1519-1524
9. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
10. John M., Constien R., Akinc A., Goldberg M., Moon Y.A., Spranger M., Hadwiger P., Soutschek J., Vornlocher H.P., Manoharan M., Stoffel M., Langer R., Anderson D.G., Horton J.D., Koteliansky V., and Bumcrot D. Effective RNAi-mediated gene silencing without interruption of the endogenous microRNA pathway. Nature 449 (2007) 745-747
11. Novina C.D., Murray M.F., Dykxhoorn D.M., Beresford P.J., Riess J., Lee S.K., Collman R.G., Lieberman J., Shankar P., and Sharp P.A. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 8 (2002) 681-686
12. Song E., Lee S.K., Wang J., Ince N., Ouyang N., Min J., Chen J., Shankar P., and Lieberman J. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9 (2003) 347-351
13. de Fougerolles A., Vornlocher H.P., Maraganore J., and Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov. 6 (2007) 443-453
14. Bumcrot D., Manoharan M., Koteliansky V., and Sah D.W. RNAi therapeutics: a potential new class of pharmaceutical drugs. Nat. Chem. Biol. 2 (2006) 711-719
15. Kim D.H., and Rossi J.J. Strategies for silencing human disease using RNA interference. Nat. Rev. Genet. 8 (2007) 173-184
16. Melnikova I. RNA-based therapies. Nat. Rev. Drug. Dis. 6 (2007) 863-864
17. DeVincenzo J., Cehelsky J.E., Alvarez R., Elbashir S., Harborth J., Toudjarska I., Nechev L., Murugaiah V., Van Vliet A., Vaishnaw A.K., and Meyers R. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 77 (2008) 225-231
18. Behlke M.A. Progress towards in vivo use of siRNAs. Mol. Ther. 13 (2006) 644-670
19. Gewirtz A.M. On future's doorstep: RNA interference and the pharmacopeia of tomorrow. J. Clin. Invest. 117 (2007) 3612-3614
20. Jackson A.L., Burchard J., Leake D., Reynolds A., Schelter J., Guo J., Johnson J.M., Lim L., Karpilow J., Nichols K., Marshall W., Khvorova A., and Linsley P.S. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 12 (2006) 1197-1205
21. Park Y.K., Park S.M., Choi Y.C., Lee D., Won M., and Kim Y.J. AsiDesigner: exon-based siRNA design server considering alternative splicing. Nucleic Acids Res. 36 (2008) W97-103
22. Marques J.T., and Williams B.R. Activation of the mammalian immune system by siRNAs. Nat. Biotechnol. 23 (2005) 1399-1405
23. Kleinman M.E., Yamada K., Takeda A., Chandrasekaran V., Nozaki M., Baffi J.Z., Albuquerque R.J., Yamasaki S., Itaya M., Pan Y., Appukuttan B., Gibbs D., Yang Z., Karikó K., Ambati B.K., Wilgus T.A., DiPietro L.A., Sakurai E., Zhang K., Smith J.R., Taylor E.W., and Ambati J. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452 (2008) 591-597
24. Judge A.D., Sood V., Shaw J.R., Fang D., McClintock K., and MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 23 (2005) 457-462
25. Hornung V., Guenthner-Biller M., Bourquin C., Ablasser A., Schlee M., Uematsu S., Noronha A., Manoharan M., Akira S., de Fougerolles A., Endres S., and Hartmann G. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 11 (2005) 263-270
26. Juliano R., Alam M.R., Dixit V., and Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 36 (2008) 4158-4171
27. Aigner A. Nonviral in vivo delivery of therapeutic small interfering RNAs. Curr. Opin. Mol. Ther. 9 (2007) 345-352
28. Chiu Y.L., and Rana T.M. siRNA function in RNAi: a chemical modification analysis. RNA, 9 (2003) 1034-1048
29. Harborth J., Elbashir S.M., Vandenburgh K., Manninga H., Scaringe S.A., Weber K., and Tuschl T. Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. Antisense Nucleic Acid Drug Dev. 13 (2003) 83-105
30. Czauderna F., Fechtner M., Dames S., Aygün H., Klippel A., Pronk G.J., Giese K., and Kaufmann J. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 31 (2003) 2705-2716
31. Braasch D.A., Jensen S., Liu Y., Kaur K., Arar K., White M.A., and Corey D.R. RNA interference in mammalian cells by chemically modified RNA. Biochemistry, 42 (2003) 7967-7975
32. Layzer J.M., McCaffrey A.P., Tanner A.K., Huang Z., Kay M.A., and Sullenger B.A. In vivo activity of nuclease-resistant siRNAs. RNA, 10 (2004) 766-771
33. Prakash T.P., Kraynack B., Baker B.F., Swayze E.E., and Bhat B. RNA interference by 2',5'-linked nucleic acid duplexes in mammalian cells. Bioorg. Med. Chem. Lett. 16 (2006) 3238-3240
34. Dande P., Prakash T.P., Sioufi N., Gaus H., Jarres R., Berdeja A., Swayze E.E., Griffey R.H., and Bhat B. Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2'- O- alkyl modification. J. Med. Chem. 49 (2006) 1624-1634
35. Iiao H., and Wang J.H. Biomembrane-permeable and ribonuclease-resistant siRNA with enhanced activity. Oligonucleotides 15 (2005) 196-205
36. Hall A.H., Wan J., Shaughnessy E.E., Ramsay Shaw B., and Alexander K.A. K.A. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 32 (2004) 5991-6000
37. Felgner P.L., Holm M., and Chan H. Cationic liposome-mediated transfection. Nature, 337 (1989) 387-388
38. Lv H., Zhang S., Wang B., Cui S., and Yan J. Toxicity of cationic lipids and cationic polymers in gene delivery. J. Control. Release, 114 (2006) 100-109
39. Kim H.S., Song I.H., Kim J.C., Kim E.J., Jang D.O., and Park Y.S. In vitro and in vivo gene-transferring characteristics of novel cationic lipids, DMKD (O,O'-dimyristyl-N-lysyl aspartate) and DMKE (O,O'-dimyristyl-N-lysyl glutamate). J. Control. Release 115 (2006) 234-241
40. Obata Y., Suzuki D., and Takeoka S. Evaluation of cationic assemblies constructed with amino acid based lipids for plasmid DNA delivery. Bioconjug. Chem. 19 (2008) 1055-1063
41. Akinc A., Zumbuehl A., Goldberg M., Leshchiner E.S., Busini V., Hossain N., Bacallado S.A., Nguyen D.N., Fuller J., Alvarez R., Borodovsky A., Borland T., Constien R., de Fougerolles A., Dorkin J.R., Narayanannair K., Jayaraman M., John M., Koteliansky V., Manoharan M., Nechev L., Qin J., Racie T., Raitcheva D., Rajeev K.G., Sah D.W., Soutschek J., Toudjarska I., Vornlocher H.P., Zimmermann T.S., Langer R., and Anderson D.G. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 26 (2008) 561-569
42. Kim H.R., Kim I.K., Bae K.H., Lee S.H., Lee Y., and Park T.G. Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. Mol. Pharm. 5 (2008) 622-631
43. Morrissey D.V., Lockridge J.A., Shaw L., Blanchard K., Jensen K., Breen W., Hartsough K., Machemer L., Radka S., Jadhav V., Vaish N., Zinnen S., Vargeese C., Bowman K., Shaffer C.S., Jeffs L.B., Judge A., MacLachlan I., and Polisky B. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23 (2005) 1002-1007
44. Geisbert T.W., Hensley L.E., Kagan E., Yu E.Z., Geisbert J.B., Daddario-DiCaprio K., Fritz E.A., Jahrling P.B., McClintock K., Phelps J.R., Lee A.C., Judge A., Jeffs L.B., and MacLachlan I. Postexposure protection of guinea pigs against a lethal ebola virus challenge is conferred by RNA interference. J. Infect. Dis. 193 (2006) 1650-1657
45. Zimmermann T.S., Lee A.C., Akinc A., Bramlage B., Bumcrot D., Fedoruk M.N., Harborth J., Heyes J.A., Jeffs L.B., John M., Judge A.D., Lam K., McClintock K., Nechev L.V., Palmer L.R., Racie T., Röhl I., Seiffert S., Shanmugam S., Sood V., Soutschek J., Toudjarska I., Wheat A.J., Yaworski E., Zedalis W., Koteliansky V., Manoharan M., Vornlocher H.P., and MacLachlan I. RNAi-mediated gene silencing in non-human primates. Nature, 441 (2006) 111-114
46. Kim S.I., Shin D., Choi T.H., Lee J.C., Cheon G.J., Kim K.Y., Park M., and Kim M. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol. Ther. 15 (2007) 1145-1152
47. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Fisch G., Dames S., Löffler K., Fechtner M., Arnold W., Giese K., Klippel A., and Kaufmann J. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 13 (2006) 1222-1234
48. Peer D., Park E.J., Morishita Y., Carman C.V., and Shimaoka M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science, 319 (2008) 627-630
49. Li S.D., and Huang L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol. Pharm. 3 (2006) 579-588
50. Li S.D., Chen Y.C., Hackett M.J., and Huang L. Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol. Ther. 16 (2008) 163-169
51. Li S.D., Chono S., and Huang L. Efficient gene silencing in metastatic tumor by siRNA formulated in surface-modified nanoparticles. J. Control. Release, 126 (2008) 77-84
52. Jr Landen C.N., Chavez-Reyes A., Bucana C., Schmandt R., Deavers M.T., Lopez-Berestein G., and Sood A.K. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65 (2005) 6910-6918
53. Halder J., Kamat A.A., Jr Landen C.N., Han L.Y., Lutgendorf S.K., Lin Y.G., Merritt W.M., Jennings N.B., Chavez-Reyes A., Coleman R.L., Gershenson D.M., Schmandt R., Cole S.W., Lopez-Berestein G., and Sood A.K. Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin. Cancer Res. 12 (2006) 4916-4924
54. Gray M.J., Van Buren G., Dallas N.A., Xia L., Wang X., Yang A.D., Somcio R.J., Lin Y.G., Lim S., Fan F., Mangala L.S., Arumugam T., Logsdon C.D., Lopez-Berestein G., Sood A.K., and Ellis L.M. Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J. Natl. Cancer Inst. 100 (2008) 109-120
55. Merritt W.M., Lin Y.G., Spannuth W.A., Fletcher M.S., Kamat A.A., Han L.Y., Landen C.N., Jennings N., De Geest K., Langley R.R., Villares G., Sanguino A., Lutgendorf S.K., Lopez-Berestein G., Bar-Eli M.M., and Sood A.K. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J. Natl. Cancer Inst. 100 (2008) 359-372
56. Ma Z., Li J., He F., Wilson A., Pitt B., and Li S. Cationic lipids enhance siRNA-mediated interferon response in mice. Biochem. Biophys. Res. Commun. 330 (2005) 755-759
57. Gary D.J., Puri N., and Won Y.Y. Polymer-based siRNA delivery: perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J. Control. Release 121 (2007) 64-73
58. Grayson A.C., Doody A.M., and Putnam D. Biophysical and structural characterization of polyethylenimine-mediated siRNA delivery in vitro. Pharm. Res. 23 (2006) 1868-1876
59. Boussif O., Zanta M.A., and Behr J.P. Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene Ther. 3 (1996) 1074-1080
60. Boeckle S., von Gersdorff K., van der Piepen S., Culmsee C., Wagner E., and Ogris M. Purification of polyethylenimine polyplexes highlights the role of free polycations in gene transfer. J. Gene Med. 6 (2004) 1102-1111
61. Hunter A.C. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv. Drug Deliv. Rev. 58 (2006) 1523-1531
62. Thomas M., and Klibanov A.M. Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells. Proc. Natl. Acad. Sci. USA. 99 (2002) 14640-14645
63. Fischer D., von Harpe A., Kunath K., Petersen H., Li Y., and Kissel T. Copolymers of ethylene imine and N-(2-hydroxyethyl)-ethyleneimine as tools to study effects of polymer structure on physicochemical and biological properties of DNA complexes. Bioconjug. Chem. 13 (2002) 1124-1133
64. Ahn C.H., Chae S.Y., Bae Y.H., and Kim S.W. Biodegradable poly(ethylenimine) for plasmid DNA delivery. J Control. Release 80 (2002) 273-282
65. Mao S., Neu M., Germershaus O., Merkel O., Sitterberg J., Bakowsky U., and Kissel T. Influence of polyethylene glycol chain length on the physicochemical and biological properties of poly(ethylene imine)-graft-poly(ethylene glycol) block copolymer/siRNA polyplexes. Bioconjug. Chem. 17 (2006) 1209-1218
66. Tietze N., Pelisek J., Philipp A., Roedl W., Merdan T., Tarcha P., Ogris M., and Wagner E. Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded siRNA polyplexes for downregulation of Ran. Oligonucleotides 18 (2008) 161-174
67. Schiffelers R.M., and Storm G. ICS-283: a system for targeted intravenous delivery of siRNA. Expert Opin. Drug Deliv. 3 (2006) 445-454
68. Kim B., Tang Q., Biswas P.S., Xu J., Schiffelers R.M., Xie F.Y., Ansari A.M., Scaria P.V., Woodle M.C., Lu P., and Rouse B.T. Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes: therapeutic strategy for herpetic stromal keratitis. Am. J. Pathol. 165 (2004) 2177-2185
69. Sato A., Choi S.W., Hirai M., Yamayoshi A., Moriyama R., Yamano T., Takagi M., Kano A., Shimamoto A., and Maruyama A. Polymer brush-stabilized polyplex for an siRNA carrier with long circulatory half-life. J. Control. Release 122 (2007) 209-216
70. Davis M.E., Pun S.H., Bellocq N.C., Reineke T.M., Popielarski S.R., Mishra S., and Heidel J.D. Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers. Curr. Med. Chem. 11 (2004) 179-197
71. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., Davis M.E., and Triche T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 65 (2005) 8984-8992
72. Heidel J.D., Yu Z., Liu J.Y., Rele S.M., Liang Y., Zeidan R.K., Kornbrust D.J., and Davis M.E. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc. Natl. Acad. Sci. USA. 104 (2007) 5715-5721
73. Howard K.A., Rahbek U.L., Liu X., Damgaard C.K., Glud S.Z., Andersen M.Ø., Hovgaard M.B., Schmitz A., Nyengaard J.R., Besenbacher F., and Kjems J. RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. Mol. Ther. 14 (2006) 476-484
74. de Martimprey H., Bertrand J.R., Fusco A., Santoro M., Couvreur P., Vauthier C., and Malvy C. siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res. 36 (2008) e2
75. Pillé J.Y., Li H., Blot E., Bertrand J.R., Pritchard L.L., Opolon P., Maksimenko A., Lu H., Vannier J.P., Soria J., Malvy C., and Soria C. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. Hum. Gene Ther. 17 (2006) 1019-1026
76. Ochiya T., Takahama Y., Nagahara S., Sumita Y., Hisada A., Itoh H., Nagai Y., and Terada M. New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material:the Minipellet. Nat. Med. 5 (1999) 707-710
77. Hanai K., Takeshita F., Honma K., Nagahara S., Maeda M., Minakuchi Y., Sano A., and Ochiya T. Atelocollagen-mediated systemic DDS for nucleic acid medicines. Ann. N. Y. Acad. Sci. 1082 (2006) 9-17
78. Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., and Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 64 (2004) 3365-3370
79. Yamato K., Yamada T., Kizaki M., Ui-Tei K., Natori Y., Fujino M., Nishihara T., Ikeda Y., Nasu Y., Saigo K., and Yoshinouchi M. New highly potent and specific E6 and E7 siRNAs for treatment of HPV16 positive cervical cancer. Cancer Gene Ther. 15 (2008) 140-153
80. Takeshita F., Minakuchi Y., Nagahara S., Honma K., Sasaki H., Hirai K., Teratani T., Namatame N., Yamamoto Y., Hanai K., Kato T., Sano A., and Ochiya T. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. USA. 102 (2005) 12177-12182
81. Chiu Y.L., Ali A., Chu C.Y., Cao H., and Rana T.M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem. Biol. 11 (2004) 1165-1175
82. Muratovska A., and Eccles M.R. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett. 558 (2004) 63-68
83. Meade B.R., and Dowdy S.F. Exogenous siRNA delivery using peptide transduction domain/cell penetrating peptides. Adv. Drug Deliv. 59 (2007) 134-140
84. Moschos S.A., Jones S.W., Perry M.M., Williams A.E., Erjefalt J.S., Turner J.J., Barnes P.J., Sproat B.S., Gait M.J., and Lindsay M.A. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug. Chem. 18 (2007) 1450-1459
85. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., and Park T.G. PEG conjugated VEGF siRNA for anti-angiogenic gene therapy. J. Control. Release 116 (2006) 123-129
86. Kim S.H., Jeong J.H., Lee S.H., Kim S.W., and Park T.G. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. J. Control. Release 129 (2008) 107-116
87. Soutschek J., Akinc A., Bramlage B., Charisse K., Constien R., Donoghue M., Elbashir S., Geick A., Hadwiger P., Harborth J., John M., Kesavan V., Lavine G., Pandey R.K., Racie T., Rajeev K.G., Röhl I., Toudjarska I., Wang G., Wuschko S., Bumcrot D., Koteliansky V., Limmer S., Manoharan M., and Vornlocher H.P. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (2004) 173-178
88. Wolfrum C., Shi S., Jayaprakash K.N., Jayaraman M., Wang G., Pandey R.K., Rajeev K.G., Nakayama T., Charrise K., Ndungo E.M., Zimmermann T., Koteliansky V., Manoharan M., and Stoffel M. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25 (2007) 1149-1157
89. Song E., Zhu P., Lee S.K., Chowdhury D., Kussman S., Dykxhoorn D.M., Feng Y., Palliser D., Weiner D.B., Shankar P., Marasco W.A., and Liberman J. Antibody-mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23 (2005) 709-717
90. Kumar P., Ban H.S., Kim S.S., Wu H., Pearson T., Greiner D.L., Laouar A., Yao J., Haridas V., Habiro K., Yang Y.G., Jeong J.H., Lee K.Y., Kim Y.H., Kim S.W., Peipp M., Fey G.H., Manjunath N., Shultz L.D., Lee S.K., and Shankar P. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 134 (2008) 1-10
91. Bunka D.H., and Stockley P.G. Aptamers come of age-at last. Nat. Rev. Microbiol. 4 (2006) 588-596
92. 2nd McNamara J.O., Andrechek E.R., Wang Y., Viles K.D., Rempel R.E., Gilboa E., Sullenger B.A., and Giangrande P.H. Cell type-specific delivery of siRNAs with aptamer siRNA chimeras. Nat. Biotechnol. 24 (2006) 1005-1015
93. Chu T.C., Twu K.Y., Ellington A.D., and Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res. 34 (2006) e73
94. Zhou J., Li H., Li S., Zaia J., and Rossi J.J. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther. 16 (2008) 1481-1489
95. Jantsch J., Turza N., Volke M., Eckardt K.U., Hensel M., Steinkasserer A., Willam C., and Prechtel A.T. Small interfering RNA (siRNA) delivery into murine bone marrow-derived dendritic cells by electroporation. J. Immunol. Methods 337 (2008) 71-77
96. Novobrantseva T.I., Akinc A., Borodovsky A., and de Fougerolles A. Delivering silence: advancements in developing siRNA therapeutics. Curr. Opin. Drug Discov. Devel. 11 (2008) 217-224
97. Inoue T., Sugimoto M., Sakurai T., Saito R., Futaki N., Hashimoto Y., Honma Y., Arai I., and Nakaike S. Modulation of scratching behavior by silencing an endogenous cyclooxygenase-1 gene in the skin through the administration of siRNA. J. Gene Med. 9 (2007) 994-1001
98. Schiffelers R.M., Xu J., Storm G., Woodle M.C., and Scaria P.V. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum. 52 (2005) 1314-1318
99. Golzio M., Mazzolini L., Ledoux A., Paganin A., Izard M., Hellaudais L., Bieth A., Pillaire M.J., Cazaux C., Hoffmann J.S., Couderc B., and Teissié J. In vivo gene silencing in solid tumors by targeted electrically mediated siRNA delivery. Gene Ther. 14 (2007) 752-759
100. Leung R.K., and Whittaker P.A. RNA interference: from gene silencing to gene-specific therapeutics. Pharmacol. Ther. 107 (2005) 222-239
101. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
102. Pai S.I., Lin Y.Y., Macaes B., Meneshian A., Hung C.F., and Wu T.C. Prospects of RNA interference therapy for cancer. Gene Ther. 13 (2006) 464-477
103. Moulder S., and Hortobagyi G.N. Advances in the treatment of breast cancer. Clin. Pharmacol. Ther. 81 (2008) 26-36
104. Lavigne C., and Thierry A.R. Specific subcellular localization of siRNAs delivered by lipoplex in MCF-7 breast cancer cells. Biochimie 89 (2007) 1245-1251
105. Meryet-Figuières M., Resina S., Lavigne C., Barlovatz-Meimon G., Lebleu B., and Thierry A.R. Inhibition of PAI-1 expression in breast cancer carcinoma cells by siRNA at nanomolar range. Biochimie 89 (2007) 1228-1233
106. Hogrefe R.I., Lebedev A.V., Zon G., Pirollo K.F., Rait A., Zhou Q., Yu W., and Chang E.H. Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2. Nucleosides Nucleotides Nucleic Acids 25 (2006) 889-907
107. Sutton D., Kim S., Shuai X., Leskov K., Marques J.T., Williams B.R., Boothman D.A., and Gao J. Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int. J. Nanomedicine 1 (2006) 155-162
108. Tan W.B., Jiang S., and Zhang Y. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. Biomaterials 28 (2007) 1565-1571
109. Wang Y., Gao S., Ye W.H., Yoon H.S., and Yang Y.Y. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater. 5 (2006) 791-796
110. Chien P.Y., Wang J., Carbonaro D., Lei S., Miller B., Sheikh S., Ali S.M., Ahmad M.U., and Ahmad I. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo. Cancer Gene Ther. 12 (2005) 321-328
111. Urban-Klein B., Werth S., Abuharbeid S., Czubayko F., and Aigner A. RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther. 12 (2005) 461-466
112. Landen C.N., Merritt W.M., Mangala L.S., Sanguino A.M., Bucana C., Lu C., Lin Y.G., Han L.Y., Kamat A.A., Schmandt R., Coleman R.L., Gershenson D.M., Lopez-Berestein G., and Sood A.K. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol. Ther. 5 (2006) 1708-1713
113. Thaker P.H., Han L.Y., Kamat A.A., Arevalo J.M., Takahashi R., Lu C., Jennings N.B., Armaiz-Pena G., Bankson J.A., Ravoori M., Merritt W.M., Lin Y.G., Mangala L.S., Kim T.J., Coleman R.L., Landen C.N., Li Y., Felix E., Sanguino A.M., Newman R.A., Lloyd M., Gershenson D.M., Kundra V., Lopez-Berestein G., Lutgendorf S.K., Cole S.W., and Sood A.K. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat. Med. 12 (2006) 939-944
114. Fujii T., Saito M., Iwasaki E., Ochiya T., Takei Y., Hayashi S., Ono A., Hirao N., Nakamura M., Kubushiro K., Tsukazaki K., and Aoki D. Intratumor injection of small interfering RNA- targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer. Int. J. Oncol. 29 (2006) 541-548
115. Arbuthnot P., Longshaw V., Naidoo T., and Weinberg M.S. Opportunities for treating chronic hepatitis B and C virus infection using RNA interference. J. Viral Hepat. 14 (2007) 447-459
116. Morrissey D.V., Blanchard K., Shaw L., Jensen K., Lockridge J.A., Dickinson B., McSwiggen J.A., Vargeese C., Bowman K., Shaffer C.S., Polisky B.A., and Zinnen S. Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology 41 (2005) 1349-1356
117. Yano J., Hirabayashi K., Nakagawa S., Yamaguchi T., Nogawa M., Kashimori I., Naito H., Kitagawa H., Ishiyama K., Ohgi T., and Irimura T. Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin. Cancer Res. 10 (2004) 7721-7726
118. Zhang C., Tang N., Liu X., Liang W., Xu W., and Torchilin V.P. siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J. Control. Release 112 (2006) 229-239
119. Pirollo K.F., Zon G., Rait A., Zhou Q., Yu W., Hogrefe R., and Chang E.H. Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. Hum. Gene Ther. 17 (2006) 117-124
120. Zhang Z., Yang X., Zhang Y., Zeng B., Wang S., Zhu T., Roden R.B., Chen Y., and Yang R. Delivery of telomerase reverse transcriptase small interfering RNA in complex with positively charged single-walled carbon nanotubes suppresses tumor growth. Clin. Cancer Res. 12 (2006) 4933-4939
121. Park M.R., Han K.O., Han I.K., Cho M.H., Nah J.W., Choi Y.J., and Cho C.S. Degradable polyethylenimine-alt-poly (ethylene glycol) copolymers as novel gene carriers. J. Control. Release 105 (2005) 367-380
122. Xu C.X., Jere D., Jin H., Chang S.H., Chung Y.S., Shin J.Y., Kim J.E., Park S.J., Lee Y.H., Chae C.H., Lee K.H., Beck Jr. G.R., Cho C.S., and Cho M.H. Poly(ester amine)-mediated, aerosol-delivered Akt1 small interfering RNA suppresses lung tumorigenesis. Am. J. Respir. Crit. Care Med. 178 (2008) 60-73
123. Rubin M.A. Targeted therapy of cancer: new roles for pathologists-prostate cancer. Mod. Pathol. 21 Suppl 2 (2008) S44-55
124. Pal A., Ahmad A., Khan S., Sakabe I., Zhang C., Kasid U.N., and Ahmad I. Systemic delivery of Raf siRNA using cationic cardiolipin liposomes silences Raf-1 expression and inhibits tumor growth in xenograft model of human prostate cancer. Int. J. Oncol. 26 (2005) 1087-1091
125. Bisanz K., Yu J., Edlund M., Spohn B., Hung M.C., Chung L.W., and Hsieh C.L. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol. Ther. 12 (2005) 634-643
126. Santel A., Aleku M., Keil O., Endruschat J., Esche V., Durieux B., Löffler K., Fechtner M., Röhl T., Fisch G., Dames S., Arnold W., Giese K., Klippel A., and Kaufmann J. RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther. 13 (2006) 1360-1370
127. Xia C.F., Zhang Y., Zhang Y., Boado R.J., and Pardridge W.M. Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology. Pharm. Res. 24 (2007) 2309-2316
128. Grzelinski M., Urban-Klein B., Martens T., Lamszus K., Bakowsky U., Höbel S., Czubayko F., and Aigner A. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum. Gene Ther. 17 (2006) 751-766
129. Yoshizawa T., Hattori Y., Hakoshima M., Koga K., and Maitani Y. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur. J. Pharm. Biopharm. 70 (2008) 718-725
130. He W., Liu T., Chen Y.X., Cheng D.J., Li X.R., Xiao Y., and Feng Y.L. Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo. Cancer Gene Ther. 15 (2008) 193-202
131. Bartlett D.W., Su H., Hildebrandt I.J., Weber W.A., and Davis M.E. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc. Natl. Acad. Sci. USA. 104 (2007) 15549-15554